 |
Dépôt minimal $50 Promotion exclusive |
Notre score |
Commission 0% |
Are you looking to buy IonPharmaceuticals stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:IONS! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about IonPharmaceuticals stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington’s diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer’s diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson’s disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Volume moyen
934,938 shs
CAP DE MARCHÉ
$8.42 billion
Bourse
NASDAQ
Achetez cette action !
|
NOM
|
TICKER
|
INDUSTRIE
|
SECTEUR
|
VOLUME
|
ACHETEZ CETTE ACTION MAINTENANT
|
|---|---|---|---|---|---|
|
NASDAQ:IONS
|
Préparations pharmaceutiques
|
Médical
|
12,480 shs
|
Below is a quick guide on how to buy NASDAQ:IONS stocks safe, fast and around the world in less than five minutes.
Étape 1 : Ouvrir un compte chez eToro – eToro is the best broker to buy IonPharmaceuticals shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Étape 2 : Téléchargez votre ID - Conformément à la réglementation KYC, eToro vous demandera de télécharger une copie de votre passeport ou de votre permis de conduire.
Étape 3 : Dépôt des fonds - Déposez de l'argent sur votre compte eToro nouvellement créé. Vous pouvez choisir entre un virement bancaire, un portefeuille électronique, une carte de débit/crédit ou Paypal.
Étape 4 : Buy IonPharmaceuticals – Search for “”NASDAQ:IONS”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought IonPharmaceuticals stocks with 0% commission!.
1 | | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
13 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
Wall Street analysts have given Ionis Pharmaceuticals a “Hold” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Ionis Pharmaceuticals wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
2 |  | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
3 |  | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:IONS stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy IonPharmaceuticals stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy IonPharmaceuticals stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Comme eToro est une plateforme réglementée, vous devrez remplir le processus KYC, c'est une pratique standard et cela ne prend que quelques minutes. Vous devrez fournir une pièce d'identité avec photo (passeport, permis de conduire) et un justificatif de domicile (facture d'électricité, relevé bancaire).
Une fois que vous vous êtes inscrit et que vous avez vérifié votre compte, vous devrez déposer des fonds. eToro accepte les cartes de crédit/débit, les virements bancaires et également les portefeuilles électroniques. Donc, quelle que soit votre préférence, il y aura quelque chose pour vous.
Now that you’ve funded your eToro account, just type “NASDAQ:IONS stocks" dans la barre de recherche en haut de l'écran et appuyez sur "commerce".
All that’s left is to buy some NASDAQ:IONS stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:IONS is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy IonPharmaceuticals stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Ionis Pharmaceuticals.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its earnings results on Wednesday, November, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.11. The company earned $160 million during the quarter, compared to analysts’ expectations of $182.14 million. Ionis Pharmaceuticals had a net margin of 7.82% and a trailing twelve-month return on equity of 6.57%. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 earnings per share.
View Ionis Pharmaceuticals’ earnings history.
Ionis Pharmaceuticals’ stock was trading at $49.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IONS stock has increased by 21.8% and is now trading at $59.84.
13 equities research analysts have issued 12 month price targets for Ionis Pharmaceuticals’ shares. Their forecasts range from $34.00 to $91.00. On average, they anticipate Ionis Pharmaceuticals’ share price to reach $62.80 in the next year. This suggests a possible upside of 4.9% from the stock’s current price.
View analysts’ price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:IONS stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Plus de 95% des fonds des clients sont conservés hors ligne, en chambre froide, ce qui est crucial pour tout courtier qui gère vos actifs. Quel que soit le degré de sécurité d'une plateforme, nous vous recommandons d'utiliser le 2FA pour ajouter une couche supplémentaire de sécurité à votre compte.
eToro offre aux utilisateurs une série de fonctionnalités pour commencer à investir le plus rapidement possible. Ils ont une fonction relativement unique appelée copy trading, qui vous permet de gagner un revenu passif en reproduisant des traders expérimentés, cela vous permet de commencer à gagner du profit rapidement, et vous donne une meilleure compréhension des stratégies utilisées par les professionnels. De plus, eToro permet aux utilisateurs d'investir dans des portefeuilles gérés, un portefeuille géré étant une variété d'actifs similaires regroupés, vous permettant de diversifier votre compte, réduisant ainsi tout risque potentiel. Pour ceux qui ont déjà une expérience du trading, vous pouvez investir dans des marchés autres que les actions, car eToro permet aux utilisateurs de négocier des ETF, des matières premières, des crypto et des indices. Si vous investissez déjà en dehors de l'espace boursier, cela peut être très utile, car cela vous permet de gérer tous vos investissements en un seul endroit.
Ionis Pharmaceuticals’ management team includes the following people:
Dr. Stanley T. Crooke, Founder & Exec. Chairman (Age 76, Pay $1.97M)
Dr. Brett P. Monia, Founder, CEO & Director (Age 60, Pay $1.06M)
Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 59, Pay $834.19k)
Mr. Patrick R. O’Neil, Exec. VP of Legal, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $816.23k)
Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 67, Pay $1.36M)
Dr. Richard S. Geary, Exec. VP & Chief Devel. Officer (Age 63, Pay $829.79k)
Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 64)
Mr. D. Wade Walke, VP of Investor Relations
Ms. Roslyn Patterson M.B.A., VP of Marketing & Communications
Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of IONS’s competitors.
Les CFD sont des instruments complexes et comportent un risque élevé de perdre rapidement de l'argent en raison de l'effet de levier. 68% des comptes d'investisseurs particuliers perdent de l'argent lorsqu'ils négocient des CFD avec ce fournisseur. Vous devez vous demander si vous comprenez le fonctionnement des CFD et si vous pouvez vous permettre de prendre le risque élevé de perdre votre argent.
Based on aggregate information from Reportlab watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol “IONS.”
Ionis Pharmaceuticals’ stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (14.97%), First Trust Advisors LP (0.99%), Sumitomo Mitsui Trust Holdings Inc. (0.55%), Pinnacle Associates Ltd. (0.40%), Swiss National Bank (0.36%) and Dowling & Yahnke LLC (0.34%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O’neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.
IONS stock was sold by a variety of institutional investors in the last quarter, including Dowling & Yahnke LLC, AJO LP, Pinnacle Associates Ltd., BLB&B Advisors LLC, Sicart Associates LLC, Zurcher Kantonalbank Zurich Cantonalbank , Swiss National Bank, and First Trust Advisors LP. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Joseph Klein III, Patrick R O’neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.
1 | | Dépôt minimal $50 Promotion exclusive | Notre score 10 ★★★★★ | Commission 0% |
IONS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Nisa Investment Advisors LLC, Sumitomo Mitsui Trust Holdings Inc., State of Wisconsin Investment Board, Castle Rock Wealth Management LLC, Victory Capital Management Inc., DNB Asset Management AS, and California Public Employees Retirement System.
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Revue de Interactive Brokers, Revue d'eToro, Revue DEGiro, Revue d'AvaTrade, Examen d'IG Markets, Revue des marchés IC, Revue de CMC Markets, Revue Admiral Markets et bien d'autres encore. Lisez l'une des critiques pour tout savoir sur le courtier et commencez à acheter des actions dès maintenant.
One share of IONS stock can currently be purchased for approximately $59.84.
Ionis Pharmaceuticals has a market capitalization of $8.37 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis.
Ionis Pharmaceuticals employs 817 workers across the globe.
The official website for Ionis Pharmaceuticals is www.ionispharma.com.
A Reportlab.org, nous voulons nous assurer que vous disposez de toutes les informations les plus pertinentes sur acheter des actions. Nous vous apportons les meilleurs guides sur le marché boursier avec des critiques personnelles, des informations de fond, des critiques de plateformes, des modes d'emploi et plus encore. Vous voulez obtenir d'autres informations ? Alors consultez le Actions OTC, Actions du NASDAQ, Actions du NYSE, Actions LON, Stocks FRA, Stocks ETR, Stocks EPA, Actions de la TSX ou Actions Amex. Vous cherchez des informations plus détaillées comme Stocks de 5g, actions de biotechnologie, stocks d'or et d'autres informations de notre reportlab.
How can you buy IonPharmaceuticals stock on the internet?
You can easily buy IonPharmaceuticals stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Une autre option consiste à utiliser un courtier réglementé comme Marchés IC ou Courtiers interactifs. You can an account with these brokers and start buying or trading NASDAQ:IONS stocks in a safe and complete environment to trade in.
Where to buy IonPharmaceuticals stock?
You will first want to find a licensed broker that supports NASDAQ:IONS stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:IONS stocks in a safe and complete environment.
Is NASDAQ:IONS stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:IONS stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is IonPharmaceuticals stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:IONS is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in IonPharmaceuticals stock.
How do you trade IonPharmaceuticals stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for IonPharmaceuticals stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:IONS stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell IonPharmaceuticals stock?
To sell your NASDAQ:IONS stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best IonPharmaceuticals stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:IONS stock.
Stephen connaît bien les produits financiers et a notamment une grande passion pour les marchés boursiers et leurs participants. Nous espérons que les informations fournies vous aideront. Quelque chose n'est pas tout à fait clair ? Veuillez laisser vos questions ou commentaires au bas de la page.
| Notre score ★★★★★ | |
| Notre score ★★★★★ | |
| Notre score ★★★★★ |
Bulletin d'information
Nouvelles récentes
| |
Notre score |
Commission 0% |
Toutes les actions de l'EPA Plus d'informations Actions de l'EPA Qu'est-ce que la Bourse de Paris (EPA) ? Maintenant
Données en temps réel sur les actions et les crypto-monnaies
Notifications, conseils et actualités
Guides des meilleures actions et crypto
Critiques sur les courtiers et les bourses en ligne
Reportlab Finance est un site purement informatif et n'implique en aucun cas des conseils en matière d'investissement. Tous les investissements comportent des risques et vous pouvez perdre tous vos investissements. N'investissez pas l'argent que vous ne pouvez pas vous permettre de perdre.
Reportlab Finance
38 Holburn Lane
Heckfield Green
IP21 0UB
Royaume-Uni
Copyright © 2022 Reportlab.Finance | Tous droits réservés.
